title: Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs.
abstract: Hyaluronic acid (HA) and recombinant human insulin were co-spray dried to form a dry powder suitable for inhalation (Mass Median Aerodynamic Diameter, MMAD=1 to 4 microm). Insulin systemic levels and corresponding glucose levels were monitored following administration of the microparticles to the lungs of male Beagle dogs. Release kinetics were modified by addition of excess zinc ions (Zn2+) or hydroxypropyl cellulose (HPC). HA formulations containing insulin (10%w/w) were found to extend the mean residence time (MRT) and terminal half-life (t(1/2)) when compared to spray dried pure insulin. Addition of Zn2+ also improved MRT (>9 fold), AUC/dose (2.5 fold) and Tmax (by a factor of 3) when compared to spray dried pure insulin. Addition of HPC improved MRT (>7 fold), AUC/dose (5 fold) and Tmax (by a factor of 3) when compared to spray dried pure insulin. Our results demonstrate the potential of HA-based dry powder drug delivery systems in the pulmonary controlled release of insulin.
authors.affiliation: Elan Drug Delivery Limited, 1 Mere Way, Ruddington, Nottingham, NG11 6JS, UK.
authors.forename: K
authors.initials: K
authors.lastname: Surendrakumar
authors.forename: G P
authors.initials: GP
authors.lastname: Martyn
authors.forename: E C M
authors.initials: EC
authors.lastname: Hodgers
authors.forename: M
authors.initials: M
authors.lastname: Jansen
authors.forename: J A
authors.initials: JA
authors.lastname: Blair
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D004285:Dogs; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D008297:Male; D011208:Powders
chemical_list: D003692:Delayed-Action Preparations; D007328:Insulin; D011208:Powders; D006820:Hyaluronic Acid